SOX4 inhibits GBM cell growth and induces G0/G1 cell cycle arrest through Akt-p53 axis by unknown
Zhang et al. BMC Neurology 2014, 14:207
http://www.biomedcentral.com/1471-2377/14/207RESEARCH ARTICLE Open AccessSOX4 inhibits GBM cell growth and induces G0/G1
cell cycle arrest through Akt-p53 axis
Jing Zhang1,2, Huawei Jiang1,2, Jiaofang Shao3, Ruifang Mao2, Jie Liu2, Yingying Ma2, Xuefeng Fang1, Na Zhao2,
Shu Zheng1* and Biaoyang Lin1,2,4*Abstract
Background: SOX4 is a transcription factor required for tissue development and differentiation in vertebrates.
Overexpression of SOX4 has been reported in many cancers including glioblastoma multiforme (GBM), however,
the underlying mechanism of actions has not been studied. In this study, we investigated the role of SOX4 in GBM.
Methods: Kaplan-Meier analysis was performed to assess the association between SOX4 expression levels and
survival times in primary GBM samples. Cre/lox P system was used to generate gain or loss of SOX4 in GBM cells,
and microarray analysis uncovered the regulation network of SOX4 in GBM cells.
Results: High SOX4 expression was significantly associated with good prognosis of primary GBMs. SOX4 inhibited
the growth of GBM cell line LN229, A172G and U87MG, partly via the activation of p53-p21 signaling and
down-regulation of phosphorylated AKT1. Gene expression profiling and subsequent gene ontology analysis
showed that SOX4 influenced several key pathways including the Wnt/ beta-catenin and TGF-beta signaling pathways.
Conclusions: Our study found that SOX4 acts as a tumor suppressor in GBM cells by induce cell cycle arrest and
inhibiting cell growth.Background
The sex-determining region Y (SRY) box (SOX) gene fam-
ily, characterized by the highly conserved HMG-domain
responsible for sequence specific DNA binding, encodes
transcription factors that are essential for embryonic devel-
opment, cell fate determination, differentiation, and prolif-
eration [1]. So far, twenty pairs of SOX genes have been
identified in the human and mouse genomes [2].
SOX4 has been found to be over-expressed in adenoid
cystic carcinoma (ACC), hepatocellular carcinoma, blad-
der tumors, acute myeloblastic leukemia, prostate cancer,
endometrial cancer and glioblastoma [3-8]. SOX4 was
further identified as a common transcription factors for
neoplastic transformation and progression in a large-scale
meta-analysis of cancer microarray data [9]. However,
SOX4’s mode of action in cancer is complicated as SOX4
can act either as an oncogene [4,10,11] or a tumor sup-
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unless otherwise stated.predicts poor outcome of colorectal cancer [13]. Its over-
expression in prostate cancer correlated strongly with
Gleason score [6]. Knock down of SOX4 induced apop-
tosis in prostate cancer cells [6] and adenoid cystic carcin-
oma ACC3 cells [3]. SOX4’s role in bladder is perplexing:
SOX4 is over expressed in bladder cancer tissues com-
pared to normal tissues, but strong SOX4 expression was
found to be correlated with increased patient survival
(P <0.05) of bladder cancer [4], and when introduced to
bladder cancer cell line HU609, it reduced cell viability by
promoting apoptosis and necrosis [4]. As a tumor sup-
pressor, introduction of SOX4 into hepatocarcinoma
Hep3B and HepG2 cells induced apoptosis via the caspase
cascade with caspase-1 activation [14]. In HeLa cells,
SOX4 was shown to also induce apoptosis via the caspase
dependent pathway [15].
Glioblastoma multiforme is the most common and ag-
gressive type of malignant gliomas (WHO grade IV) with
an annual incidence of 2 to 3 per 100,000 population [16].
Currently, the standard therapy for gliomas consists of
maximal surgical resection, followed by chemotherapy
[16]. However, because of its malignant features mani-
fested by fast growth and chemo- or radio-resistance, mostLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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omas within one year [17]. Others and we have showed
that SOX4 is a target of TGF-beta signaling and is in-
volved in maintaining stemness of glioma-initiating cells
[4,8,18,19]. To further understand the molecular mechan-
ism of SOX4 in GBM, in this study, we systematically
studied the function of SOX4 in GBM cells using the Cre/
lox P system to generate gain or loss of SOX4 in GBM
cells. We showed that SOX4 inhibited the growth of GBM
cells. A gene expression profiling analysis showed that
SOX4 influenced several key pathways including the Wnt/
beta-catenin and TGF-beta signaling pathways. Finally, we
showed the activation of p53-p21 signaling and down-
regulation of phosphorylated AKT1 by SOX4. These data
provide new molecular insights into how SOX4 exerts its
functions in glioma cells.
Methods
Survival analysis
Z-Scores of mRNA of SOX4 from all three platforms
(U133 microarray, Agilent and RNA Seq V2 RSEM) for
Glioblastoma Multiforme (TCGA, Provisional) dataset
were downloaded using cBioPortal [20,21]. Univariable
survival analysis was performed by the Kaplan-Meier
method and log-rank test with ‘survival’ R package ver-
sion 2.37-7 [22].
Cell lines and cell culture
Human glioma cell lines LN229, T98G, U87MG, U251MG,
A172, M059J and M059K were obtained from the
American Type Culture Collection. All cells were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM)
with 10% fetal bovine serum (FBS) and 1% penicillin-
streptomycin in a humidified incubator with 37°C and 5%
CO2.
Plasmid construction, retrovirus infection and transfection
The SOX4 gene from a vector containing SOX4-eYFP (a
gift from Carlos S. Moreno, Emory University) was cloned
by PCR and inserted into a retrovirus plasmid pBrit-HA/
Flag (Plasmid 17519, Addgene, Cambridge MA) between
the two lox P sites using restriction enzyme BamHI and
EcoRI. A 5’ primer containing a Flag tag was used and the
final construct was designed to express the Flag-SOX4-HA
fusion protein, forward primer (5’-cgcGGATCCgcgATG
GATTACAAGGATGACGACGATAAGATGgtgcagcaaacca
aca-3’), reverse primer (5’-ccggaattcGTAGGTGAAAAC
CAG-3’).
Retrovirus was packaged by co-transfect pBrit-Flag-
SOX4-HA/pBrit-Flag-HA together and pcl-Ampho plas-
mids into 293T cells with the protocol previously described
[23], SOX4 overexpression cells (named as LN229_pSFH
or A172_pSFH or U87_pSFH respectively for the cell line
used) and control cells (named as LN229_con or A172_conor U87_con respectively for the cell line used) were cul-
tured by infecting the respective GBM cell lines with the
virus. After 96hours, cells were selected in culture media
contains 800ng/ml puromycin (Sigma) for 3 weeks. Survival
cells were harvested for functional study and analysis.
For transient transfection, SOX4-HA was cloned to
the pCMV-Tag2C vector to generate the Flag-SOX4-HA
plasmid. Cre recombinase cDNA from the pACN vector
[24](a gift from Dr. Mario Capecchi, University of Utah)
was cloned into the pEGFP-N1 to construct the Cre -GFP
plasmid. Flag-HA-GFP plasmid was used as the control.
48 hours after transfection, cells were harvested for further
analysis and cell functional test.
Cell proliferation assay
Cell growth curves were obtained by measuring cell via-
bility with the Cell Counting Kit-8 (CCK-8, Dojindo,
Japan) according to the manufacturer’s instruction. 103
cells/well were seeded into 96-well plate on day zero and
then cultured for five days. Cell viability was assessed at
6 h (hours), 24 h, 72 h, and 120 h, and normalized to
the cell viability measurement at 6 h for each group.
Each group was measured in triplicate.
Cell cycle analysis
For cell cycle analysis, 5 × 105 cells from each sample were
trypsinized to make single cell suspension. The cells were
then washed with PBS and fixed in 95% ethanol. The cells
were treated with RNAse A and stained with propidium
iodide (PI) and subjected FACS analysis.
Colony formation assay
Cells were plated into 6-well plates at 400 cells/well in
DMEM culture medium and further incubated for 2 weeks
when colonies were sufficiently large for visualization. Col-
onies were then fixed in methanol and stained with 0.5%
crystal violet (Sigma). The stained cells were quantified.
Each group was measured in triplicate.
The soft agar assay was performed in 12-well plates
containing two layers of Sea Plague Agar (Invitrogen).
The bottom layer consisted of 0.8% agar in 1 ml of
DMEM with 10% FBS and the top layer consisted 103
cells of stable overexpression cells or control cells. Cells
were seeded in each well and cultured for three weeks.
Colonies were photographed under a microscope and
counted.
Reverse transcription and real-time PCR
RNAs from cell lines were extracted using TRIZOL (Invi-
trogen) and 1μg of total RNAs was reverse transcribed
into cDNAs using ReverTra Ace qPCR RT Kit (Toyobo,
Japan). For quantitative real-time PCR, 20ng of cDNAs
was used as template using the SYBR® Premix Ex Taq™ II
(Taraka, Japan). GAPDH was used as control. Primers for
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Relative expression was calculated as described [25].
Immunoblotting and analysis
Cells were washed twice with PBS and lysed in RIPA buffer
(25mM Tris HCl, pH 7.6, 150mM NaCl, 1% NP-40, 1% so-
dium deoxycholate, 0.1% SDS, 1mM PMSF [P7626, Sigma]
with the Protease Inhibitor Cocktail [Roche]). Nuclear and
cytosolic fractions were extracted using a nuclear protein
extraction kit (Beyotime, Jiangsu, China) according to the
manufacturer's instructions. Protein concentration was
determined using the BCA protein kit (23225, Thermo,
USA). Total cell lysate (30 μg) and nuclear or cytosolic
fractions (15 μg) were loaded on SDS-PAGE and elec-
trophoretically transferred to polyvinylidene difluoride
membrane (Milipore, Bedford, MA). The membranes were
blocked with 5% milk protein in TBST (0.6% Tween, 10
mM Tris pH7.6 and 150 mM NaCl in H2O) and incubated
with primary antibodies at 4°C overnight followed by incu-
bation with secondary antibody for 1h at room temperature
before exposure. Primary antibodies used were: anti-HA
antibody (1:10000, ab9110, Abcam), anti-beta-catenin anti-
body(1:2000, ab32572, Abcam), anti-p53 antibody (1:1000,
ab32389, Abcam), anti-AKT1 antibody(1:500, ab81283,
Abcam), anti-AKT1p antibody(1:500, ab81283, Abcam),
anti-p21 antibody(1:500, AM2385, Abzoom),anti-Ki67
antibody(1:250, ab92742, Abcam), anti-GAPDH anti-
body (1:2500, ab9485, Abcam), anti-Histone H3 antibody
(1:2500, 2134–1,Epitomics), Anti-beta Catenin (phospho
S33 + S37) antibody (1:1000, ab75777, Abcam).
Expression profiling and Gene Ontology analysis
In order to identify genes subjected to SOX4’s regulation
in GBM cells, total RNAs from SOX4 overexpression
stable cell lines LN229_pSFH and LN229_con were used
for expression profiling using the PrimeView Human
Gene Expression Array (Affymetrix) using a standard
Affymetrix protocol. The array data were submitted to
the GEO database (GSE51301). Gene Ontology analysis
was done using the DAVID program (http://david.abcc.
ncifcrf.gov/) [26,27].
Statistical analysis
Statistical analysis was performed using the Student’s t-
test. P <0.05 was considered to be statistically significant.
The results are reported as mean ± SD.
Results
High SOX4 expression was significantly associated with
good prognosis of primary GBMs
We have previously reported that SOX4 is over-
expressed in primary GBM tissues compared to normal
brain tissues [8]. In this study, we analyzed the expres-
sion level of SOX4 and its association with GBM patientsurvival using the data from TCGA (Additional file 2:
Table S2) including data from all three analytical plat-
forms (U133 microarray, Agilent and RNA Seq V2
RSEM). We downloaded the data using cBioPortal
[20,21]. The expression levels of the SOX4 in the down-
loaded data were computed and represented as the Z-
scores, which are the number of standard deviations
away from the mean of expression in the population. 85
patients with SOX4 mRNA Z-Scores >1 were grouped
into the high-SOX4 group, and 79 patients with Z-
Scores < −1 into the low-SOX4 group. The remaining
331 patients were regarded as the median-SOX4 group.
Using Kaplan-Meier survival analysis, we found that the
overall survival status was significantly different between
the groups with different SOX4 expression level (logrank
test p-value =0.0104). The hazard ratio of the low-SOX4
is 1.65, and the hazard ratio of the median-SOX4 group
is 1.46, which are both significantly greater compared with
the hazard ration of 1 in the high-SOX4 group (P values
of 0.006 and 0.0073 respectively (Figure 1), indicating that
high SOX4 expression is strongly associated with the good
prognosis of GBM patients.Overexpression of SOX4 reduces cell proliferation and
colony formation in GBM cells
To understand the protective mechanism of goof prog-
nosis of high expression SOX4 for GBM patients, we de-
cided to overexpress the SOX4 gene in GBM cell lines
and to assess its impact on cell proliferation and colony
formation. In order to find a suitable GBM cell lines for
overexpression SOX4, we compared the SOX4 expres-
sion at mRNA levels for seven GBM cell lines LN229,
T98G, U87, U251, A172, M059J and M059K by real-
time PCR (Additional file 3: Figure S1). We found that
GBM cell line LN229 have relative lower expression of
SOX4 than others.
We started with testing the functional consequences of
SOX4 overexpression using a transient expression system.
We transiently transfected GBM cell line LN229 with the
Flag-SOX4-HA construct and we used the empty vector
pEGFP-N1 construct without the HA tag as the control.
Forty-eight hours after transfection, we detected marked in-
crease of SOX4 protein expression in LN229 cells by west-
ern blot with anti-HA antibody (Figure 2A), as shown by
the band at 70 KDa for the Flag-SOX4-HA protein [10,28].
By cell proliferation assay, we found that LN229 cells
with transient SOX4 overexpression grew significantly
slower than cells with the control construct (Figure 2B). In
addition, SOX4 overexpression cells lost the ability to
form colonies (Figure 2C). FACs analysis showed an in-
creased accumulation of SOX4 overexpression LN229
cells in the G0/G1 phase (65.3%) compared with the cells
with Flag-HA-GFP control (59.6%), p < 0.05 (Figure 2D).
Figure 1 Kaplan-Meier analysis comparing SOX4 mRNA status with survival in primary GBM samples. Z-Scores of mRNA of SOX4 (TCGA,
Provisional) were downloaded using cBioPortal. Kaplan-Meier survival analysis of SOX4 expression in primary GBM showed the overall survival status
was significantly different between the groups with different SOX4 expression level. The hazard ratio of low-SOX4(Z-Score < 1) or median-SOX4
(Z-Score = 1)patients was larger than high-SOX4(Z-Score > 1)with p-value < −0.01.
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decided to stably over express SOX4 in GBM cells. In
order to easily remove the SOX4 in the overexpression
construct as a way to study functional reversal, we decided
to use a Cre/lox P recombination system to engineer
SOX4 overexpression. GBM cell lines LN229, A172,
U87MG were selected to over-express Flag-SOX4-HA by
retroviral infection. After selected with 800ng/ml puro-
mycin for three weeks, cells were harvested and their ex-
pression of exogenous Flag-SOX4-HA were validated by
real-time PCR and western blot (Figure 3A).
SOX4 overexpression cells in all of the three cell lines
LN229, A172, U87MG showed reduced cell proliferation
with stable SOX4 expression (Figure 3B). LN229_pSFH
and A172_pSFH showed reduced colony formation cap-
abilities compared with LN229_con and A172_con cells
(Figure 3C). For U87 GBM cell lines, because SOX4
overexpression changed its morphology (Additional file
4: Figure S2), we did soft agar assay instead. After being
cultured in suspended condition for three weeks, col-
onies of U87_con were visible by eyes while U87_pSFH
could not form sphere from single cell (Figure 3D). In
summary, SOX4 overexpression inhibits cell prolifera-
tion in GBM cells and also blocked the anchorage-
independent growth ability of U87 GBM cells.
Knock out SOX4 by Cre recombinase promotes cell
proliferation in LN229 cells
To see whether the effect of SOX4 overexpression on cell
proliferation is reversible, we took advantage of the loxP
system in our construct where the SOX4 gene can be re-
moved after introducing Cre recombinase to the cells. To
estimate the potential influence of Cre recombinase oncell, we did transient transfection of Cre-GFP construct
into LN229 cells and no significant changes on cell pro-
liferation or colony formation ability of LN229 cells
were found (Figure 2B and C). 48 hours after transfec-
tion of Cre-GFP plasmid, exogenous SOX4 expression
was reduced about 50% in LN229_pSFH cells with Cre
recombinase compared with the control cells without
Cre (transfected with the pEGFP-N1 plasmid instead)
(Figure 4A), and the cell proliferation increased dramat-
ically at day 5 in LN229_pSFH cells with Cre recombinase
compared to that for the control cells (Figure 4B). Flow
cytometry analysis showed a decreased accumulation of
cells in the G0/G1 phase (65%) for pSFH cells transfected
with Cre-GFP compared with that for pSFH cells trans-
fected with pEGFP-N1 (75.9%), although pSFH cells trans-
fected with Cre still have higher number of cells at G0/G1
phase (65%) compared with that in LN229_con cells
(60.8%) (Figure 4C). These data suggested that SOX4 sup-
pressed GBM cell proliferation by inducing G0/G1 cell
cycle arrest.
Global expression profiling of SOX4 regulated genes
To identify genes regulated by SOX4 in GBM cells, we
used Affymetrix’s The GeneChip® PrimeView™ Human
Gene Expression Array to compare SOX4 overexpres-
sion LN229_pSFH and LN229_con cells. We identified
633 genes were changed more than 1.8 fold (Additional
file 5: Table S3). The array data was confirmed by doing
real-time PCR, and 9 of 10 randomly selected changed
genes identified by array was confirmed by RT-PCR
(Figure 5A).
We performed GO analysis with 633 SOX4 regulated
genes and found that they are enriched in biological
Figure 2 Transient SOX4 overexpression inhibits growth of LN229 cells and induces G0/G1 cell cycle arrest. (A) LN229 cells were
transiently transfected with Flag-Sox4-HA or pEGFP-N1 plasmid as control. After 48 hours, protein expression was assayed by Western blotting
using anti-HA antibody (B) Cell vitality was determined by CCK-8 assay after transfection of LN229 cells with Flag-Sox4-HA plasmid or pEGFP-N1
and Cre-GFP as control at the indicated time points. Values at the indicated time points were provided as the mean cell number with an SD of
eight wells. *, P < 0.05 (C) Colonies formed by Flag-Sox4-HA or pEGFP-N1or Cre-GFP infected LN229 cells were shown 2 weeks after plating in 6
well plate. Upper panel showed the quantification of the colony in Flag-Sox4-HA or pEGFP-N1or Cre-GFP infected LN229 cells. Values are the
means ± SD of triplicate experiments, *P < 0.05 (D) Impact of SOX4 on cell cycle of LN229 cells. The percentage of cells in G0/G1, S, and G2/M
phases is shown in the left panel. And the statistic analysis is also shown in the right panel.
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Figure 3 Overexpression of SOX4 reduces proliferation and colony formation of GBM cells. (A) Validation of SOX4 expression in stable
SOX4 overexpression cells (LN229_pSFH/A172_pSFH/U87_pSFH) and control cells (LN229_con/A172_con/U87_con) by Real-time PCR and Western
blot with anti-HA antibody. (B) The vitality of GBM cells stably express Flag-SOX4-HA or GFP was determined by CCK8 assay. Values at the indicated
time points were provided as the mean cell number with an SD of eight wells. *, P < 0.05 (C) Colonies formed by LN229_pSFH/A172_pSFH or
LN229_con/A172_con were shown 2 weeks after plating in 6 well plate. Right panel showed the quantification of the colony formation. Values are the
means ± SD of triplicate experiments. *, P < 0.05 (D) Colonies formed by U87_pSFH or U87_con were shown 3 weeks after plating in Soft agar.
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DNA replication, GO:0006974_response to DNA dam-
age stimulus, GO:0007017 ~ microtubule-based process,
GO:0007010 ~ cytoskeleton organization, GO:0000075 ~
cell cycle checkpoint with p-value < 0.001, FDR < 0.05
(Table 1). We also compared our list of SOX4 regulated
genes in GBM cells to a previously published list of SOX4
regulated genes in prostate cancer cells [23], and we foundthat 54 genes are commonly changed in both glioma and
prostate cancer in response to SOX4, with 33 genes up-
regulated and 14 genes down-regulated genes (Additional
file 5: Table S3).
SOX4 was previously shown to enhance beta-catenin/
TCF activity and the proliferation of colorectal cancer cells
[29,30]. Overexpression of SOX4 in endometrial car-
cinomas cell lines caused enhancement of beta-catenin/
Figure 4 Knock out SOX4 by Cre recombinase restored cell growth and colony formation. (A) Validation of SOX4 expression in Flag-SOX4-HA
stable expressed cells transfected with Cre-GFP or pEGFP-N1 by Real-time PCR and Western blot with anti-HA antibody (B) Cell vitality was determined
by CCK-8 assay after transfection of Flag-SOX4-HA stable expressed cells with Cre-GFP or pEGFP-N1 as control. Values at the indicated time points were
provided as the mean cell number with an SD of eight wells. *P < 0.05 (C) The reduction of SOX4 reduced cells accumulated in G0/G1 phase. The
percentage of cells in G0/G1, S, and G2/M phases is shown in the left panel. And the statistic analysis is also shown in the right panel.
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pressing SOX4 demonstrated a low proliferation rate,
through transactivation of the p21 gene [31]. From our
microarray data, we also found that beta-catenin is up-
regulated by SOX4 (Additional file 5: Table S3) in GBM
cell line LN229. We further confirmed that beta-catenin is
up-regulated by SOX4 by RT-PCR and western blot in
all of the three GBM cell line LN229, A172 and U87
(Figure 5B). Additionally, Ser 33 and Ser 37 phospho-
rylation of beta-catenin by GSK3B was also increased
(Figure 5C). Western blot analysis with nuclear and cyto-
plasmic fractions of cellular proteins indicated a strong
increasment of beta-catenin in the cytoplasm but little if
any changes in the nuclear after SOX4 overexpression
(Figure 5D).SOX4 reduces cell proliferation and causes cell cycle
arrest via Akt-p53 axis
Previously studies have established that SOX4 interacts
with and stabilizes p53 protein, a key tumor suppressor
for cancers [14,32-34]. To assess whether p53 is involved
in SOX4 mediated inhibition of cell proliferation and
cell cycle arrest in GBM cells, we determined the expres-
sion of p53 and its downstream target p21, which is as-
sociated with growth arrest [35], by Western blot. We
found that both p21 and p53 proteins were increased by
SOX4 (Figure 6A). We further showed that both SOX4
and p53 proteins were accumulated in the nucleus after
SOX4 overexpression in GBM cells (Figure 6B).
Akt enhances Mdm2-mediated ubiquitination and
degradation of p53 [36]. We therefore analyzed Akt and
Table 1 Biology process enriched in SOX4 regulated gene
in LN229_pSFH cells by GO analysis
GO Annotation Count P Value
GO:0007049 Cell cycle 187 8.05E-40
GO:0006260 DNA replication 59 4.30E-18
GO:0006974 Response to DNA damage stimulus 78 5.92E-13
GO:0033554 Cellular response to stress 96 3.11E-10
GO:0007010 Cytoskeleton organization 73 9.30E-08
GO:0008283 Cell proliferation 68 3.62E-06
GO:0010941 Regulation of cell death 100 4.56E-04
GO:0006916 Anti-apoptosis 33 0.001012965
GO:0045596 Negative regulation of cell
differentiation
34 0.001139053
Figure 5 Microarry analysis of genes regulated by SOX4 in LN229 SOX4 overexpressed cells. (A) Validation of SOX4 regulated gene by
Real-time PCR. The relative expression of target gene was normalized to the endogenous control GAPDH. Three replicate PCR were performed
and the standard errors of the mean were indicated by error bars. (B) Validation of SOX4 increased beta-catenin in LN229_pSFH/A172_pSFH/
U87_pSFH compare to LN229_con/A172_con/U87_con cells by RT-PCR and Western blotting with anti beta-catenin antibody. (C) Validation of
SOX4 increased beta-catenin in LN229_pSFH/A172_pSFH compare to LN229_con/A172_con by Western blotting with anti phosphor-beta-catenin
antibody. (D) Validation of cellular localization of SOX4 increased beta-catenin. Anti-histone H3 antibody was used to normalize the amount of
nuclear sample.
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and found that both the protein levels of AKT1 (official
gene name for Akt) and phosphorylated AKT1p were
down-regulated by SOX4 overexpression (Figure 6A). We
showed earlier with the microarry data that MDM2, a key
modulator of p53 protein levels in cells by binding to p53
and promotes p53 degradation via the ubiquitin/prote-
asome pathway, is downregulated by SOX4 in LN229
(Figure 5A). Furthermore, Ki67, a proliferation marker
[37], was also found to be reduced in SOX4 overexpres-
sion GBM cells at both the mRNA (Figure 5A) and the
protein levels (Figure 6A). Thus it seemed that SOX4 in-
duced p53 in the nucleus is partially caused by down regu-
lation of AKT1 and reduced phosphorylated AKT1p.
Discussion
We reported our finding that high SOX4 expression was
significantly associated with good prognosis of primary
GBM patients (Figure 1). However, overexpression of
SOX4 in GBM cell lines inhibited cell proliferation and
G0/G1 cell cycle arrest (Figures 2 and 3). These seemly
contradictory observations between observation in pri-
mary clinical samples and in vitro cell line functional ana-
lysis is similar to what Aaboe et al. observed in bladdercancer [4]. They found that SOX4 is over expressed in
bladder cancer tissues compared to normal tissues, but
strong SOX4 expression was found to be correlated with
increased patient survival (P <0.05) of bladder cancer pa-
tients [4], and when introduced to bladder cancer cell line
HU609, it reduced cell viability by promoting apoptosis
and necrosis [4]. The exact mechanism of this seemly
contradict phenomena need further investigation. Sox
Figure 6 Validation of genes regulated by SOX4. (A) Validation
expression of p53, AKT1, AKT1p, p21 and Ki67 in Flag-SOX4-HA
stable expressed cells compare to control cells using western blot
(B) Validation of cellular localization of SOX4 and p53. Anti-histone
H3 antibody was used to normalize the amount of nuclear sample.
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depending on the cellular context and associated interact-
ing proteins [38]. One of the differences between the cell
lines we used and the GMB tumor tissues is the P53 muta-
tion status. P53 are often mutated in GBM tumors, seen
in 25–30% of primary GBM and 60–70% of secondary
GBM [39]. However, the GBM cell line LN229, A172 and
U87 that we used in the study turned out to contain wide
type p53 [40]. One possible mechanism is that SOX4
acts differently on the wild-type P53 than the mutated
P53. Further experimentation is needed to verify this
speculation.
The p53 protein is an important tumor suppressor
that is inactivated in most tumors. It controls growth ar-
rest and apoptosis by its transcriptional activation and
repression of target genes [41]. p53 is thought to exert
its function in G1 checkpoint control mainly through in-
creased expression of the p21 gene [42]. We found p53
were increased and were accumulated in the nucleus
with SOX4 (Figure 6B), while p53’s downstream target
p21 was up-regulated (Figure 6A), and leading to G0/G1
cell cycle arrest (Figure 4C). In addition, SOX4 reduced
expression levels of AKT1 and phosphorylated AKT1
(Figure 5A), which could enhance Mdm2-mediated ubi-
quitination and degradation of p53 [36,43]. Thus, we
propose a model to explain SOX4’s action in GBM cell
lines: SOX4 could down-regulate Akt, which might re-
sult in increased stability of p53, as shown by increased
p53 protein expression in SOX4 overexpressed GBM cell
lines and induced p21 signal which leading to G0/G1
cell cycle arrest.SOX4 has been proposed either as an oncogenor or a
tumor suppressor. Our finding that SOX4 acts as a tumor
suppressor in GBM is consistent with previously reported
roles of SOX4 as a tumor suppressor. For example, SOX4
induces cell apoptosis through caspase activation in hepa-
tocarcinoma cells and HeLa cells [14,15]. Nuclear overex-
pression of SOX4 in HCC samples is correlated with
diminished risk of recurrence and improved overall sur-
vival time in HCC patients [32]. Pan et al. reported that
SOX4 promotes cell cycle arrest and apoptosis, and in-
hibits tumorigenesis by blocking Mdm2-mediated p53
degradation and facilitating p300/CBP/p53complex forma-
tion [34]. In lung cancer cell line H1299, SOX4 increases
PUMA expression in response to trichostatin A (TSA)
and induces apoptosis in a p53 independent manner [44].
Our data proved that SOX4 inhibited cell growth and
induced G0/G1 cell cycle arrest in GBM cells. We found
that AKT1 and AKT1p were reduced while SOX4 over-
expression in GBM and p53 protein level was increased
and co-localized in nuclear with SOX4. However, SOX4
increased beta-catenin expression seems to limited to
the cytoplasm and failed to initiate cytoplasm-to-nuclear
translocation of beta-catenin, suggesting the action of
SOX4 seems unlikely to involve directly transcriptional
changes of beta-catenin directly regulated genes.
Microarray analysis showed that SOX4 regulated genes
were enriched in Gene Ontology terms related to cell
cycle progression (Table 1 and Additional file 5: Table
S3), consistent with our functional assay showing SOX4’s
role in cell cycles. We also identified many interesting
genes regulated by SOX4, suggesting SOX4’s diverse
roles in cancer cells. For example, we found SOX2 is up-
regulated by SOX4 (Additional file 5: Table S3), which is
consistent with previous findings that the transforming
growth factor-β (TGF-β)-Sox4-Sox2 pathway is essential
for glioma-initiating cells to retain their stemness [18,19].
We also identified several other genes involved in TGF-
beta signaling include BMP2 and SOX10, whose ex-
pression were also changed after SOX4 overexpression
(Additional file 5: Table S3).
Finally, we demonstrated that beta-catenin was upregu-
lated by SOX4 (Figure 5B-D), suggesting a role of SOX4
in WNT signaling in GBM cells. SOX4 was previously
shown to enhance beta-catenin/TCF activities in several
cancer types [29-31]. p53 can reduce the proliferation-
supporting effect of beta-catenin/TCF signaling by down-
regulating Tcf-4 expression even with transcriptional
activation by beta-catenin in the nucleus [45]. Considering
SOX4 increased both p53 and beta-catenin in GBM cells,
there might be a cross talk between these two signals.
Conclusions
We showed that high SOX4 expression was significantly
associated with good prognosis of primary GBM patients,
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http://www.biomedcentral.com/1471-2377/14/207suggesting the SOX4 might be a prognosis marker for
GBM. However, in cell line models of GBM, SOX4 seems
to behave as a tumor suppressor, a discrepancy to the
good prognosis offered by the high SOX4 expression. Fur-
ther investigation is necessary to understand this discrep-
ancy and to determine the different cellular contexts in
cancer cells that turn SOX4 into a tumor suppressor or
tumor promoter.
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